Recent

% | $
Quotes you view appear here for quick access.

YM BioSciences, Inc. Ordinary S Message Board

  • mdv_92126 mdv_92126 Feb 2, 2006 7:15 PM Flag

    Pancreatic cancer

    Sean Thompson will be participating in the focus session "Cancer: A Glimmer of Hope - Pancreatic Cancer Treatment Strategies" on Feb 15 at 8:30AM EST in the Jade Room at the BIO CEO Conference.


    why? YMI has something that works?
    NIMO results due 2nd QTR.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • well,

      YMI trades up for a few days...

    • FEBRUARY 13, 2006



      Gene Marcial



      STORY TOOLS
      Printer-Friendly Version
      E-Mail This Story
      Reader Comments



      RELATED ITEMS


      INSIDE WALL STREET

      Watch It, Counterfeiters

      Apoplexy: Renovis Takes Aim

      YM Biosciences' Cancer Drugs Are Working


      RELATED ITEMS

      Inside Wall Street Archive

      � Find More Stories Like This


      INSIDE WALL STREET

      YM Biosciences' Cancer Drugs Are Working

      Another tiny biotech, YM Biosciences (YMI ), trading on the Amex, may also have a winner: Tesmilifene for metastatic breast cancer. Now in Phase III trials, Tesmilifene has been shown to improve the effectiveness of commonly used chemotherapies in prolonging life. In January, YM signed a pact with Sanofi-Aventis (SNY ) to investigate the effect of combining Tesmilifene with Sanofi's Docetaxel to treat fast-growing tumors. The study will test whether using Tesmilifene together with Docetaxel enhances the survival of seriously ill patients without increasing toxicity. Initial research will be conducted in Europe and the U.S. Another YM product, for brain cancer, will go into Phase III trials soon. Mitchell Kaye of XmarkCapital Partners, the lead investor, with 10%, says Tesmilifene could generate annual sales of $1 billion. Now at 3.53 a share, YM could hit 15 in a year, Kaye figures. He also expects good results from trials of YM's AeroLef, an inhaler that provides quick pain relief to cancer victims, to be posted soon. Maher Yaghi of Desjardins Securities, who rates YM a buy, sees it making money in 2009 on projected sales of $36 million, and $43 million in 2010

    • www.businessweek.com/magazine/content/06_07/b3971135.htm


      ok it works now .... thnkx !

    • thnkx, but doesn;t work ?

    • ...I get it on-line. Will look it up and advise...Bill

      PS...Haven't got any of your recent e-mails.
      Please try again....fghton@sbcglobal.net
      Thanks...

      • 1 Reply to fghton
      • ...."YM Biosciences'Cancer Drugs Are Working"...

        Talks about Tesmilifene and a "Mitchell Kaye of Xmark Capital Partners, the lead invetor, with 10%, says Tesmilifene could generate annual sales of 1 billion. Now 3.53 a share, YM could hit 15 in a year, Kaye figures. He also expects good results from trials of YM's AeroLef, an inhaler that provides quick pain relieft to cancer victims, to be posted soon. Maher Yaghi of Desjardins Securities, who rates YM a buy, sees it making money in 2009 on projected sales of $26 million and $43 million in 2010"...